Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics

References

• National Institute of Health. Schizophrenia. Available at: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml [Last accessed 9 June 2017]
   Google Scholar
• Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care 2005;11(8Suppl):S235-S41
   Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014;10:425-48
   PubMed Web of Science ®Google Scholar
• Nordentoft M, Wahlbeck K, Hallgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013;8:e55176
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The Economic Burden of Schizophrenia in the United States in 2013. J Clin Psychiatry 2016;77:764-71
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015;72:1172-81
   PubMed Web of Science ®Google Scholar
• Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 2014;71:1350-63
   PubMed Web of Science ®Google Scholar
• Correll CU, Ng-Mak DS, Stafkey-Mailey D, et al. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry 2017;16:9
   PubMed Web of Science ®Google Scholar
• Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci 2014;264:3-28
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2Suppl):1-56
   Web of Science ®Google Scholar
• Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609-16
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114-26
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2008;2:67-77
   PubMedGoogle Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs 2016;30:689-701
   PubMed Web of Science ®Google Scholar
• Janssen CNS. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension US prescribing information. 2015. Available at: http://www.janssencns.com/shared/product/invegasustenna/prescribing-information.pdf [Last accessed 8 June 2017]
   Google Scholar
• Bossie CA, Fu DJ, Sliwa JK, et al. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol 2011;1:111-24
   PubMedGoogle Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015;169:393-9
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry 2017;17:207
   PubMed Web of Science ®Google Scholar
• Xiao Y, Muser E, Lafeuille MH, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. J Comp Eff Res 2015;4:579-92
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Dean J, Carter V, et al. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin 2014;30:1643-55
   PubMed Web of Science ®Google Scholar
• Pesa JA, Muser E, Montejano LB, et al. Costs and resource utilization among medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes 2015;2:377-85
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simulat Comput 2009;38:1228-34
   Web of Science ®Google Scholar
• Ballon J, Stroup TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry 2013;26:208-13
   PubMed Web of Science ®Google Scholar
• Morrato EH, Parks J, Campagna EJ, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. J Comp Eff Res 2015;4:89-99
   PubMed Web of Science ®Google Scholar
• Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16:231-9
   PubMedGoogle Scholar